These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23313564)

  • 41. Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder.
    Bodkin JA; Allgulander C; Llorca PM; Spann ME; Walker DJ; Russell JM; Ball SG
    Hum Psychopharmacol; 2011 Apr; 26(3):258-66. PubMed ID: 21678494
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
    Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
    Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder.
    Nardi AE; Lopes FL; Valença AM; Freire RC; Nascimento I; Veras AB; Mezzasalma MA; de-Melo-Neto VL; Soares-Filho GL; King AL; Grivet LO; Rassi A; Versiani M
    Psychiatry Res; 2010 Feb; 175(3):260-5. PubMed ID: 20036427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
    Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition.
    Freeman MP; Hirschberg AM; Wang B; Petrillo LF; Connors S; Regan S; Joffe H; Cohen LS
    Maturitas; 2013 Jun; 75(2):170-4. PubMed ID: 23602542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
    Carter CS; Fawcett J; Hertzman M; Papp LA; Jones W; Patterson WM; Swinson RP; Weise CC; Maddock RJ; Denahan AQ
    J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression.
    Dreimüller N; Schlicht KF; Wagner S; Peetz D; Borysenko L; Hiemke C; Lieb K; Tadić A
    Neuropharmacology; 2012 Jan; 62(1):264-9. PubMed ID: 21803060
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression.
    Nelson JC
    J Clin Psychopharmacol; 2011 Oct; 31(5):682-4. PubMed ID: 21881463
    [No Abstract]   [Full Text] [Related]  

  • 54. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
    Pangallo B; Dellva MA; D'Souza DN; Essink B; Russell J; Goldberger C
    J Psychiatr Res; 2011 Jun; 45(6):748-55. PubMed ID: 21511276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
    Fava M; Mallinckrodt CH; Detke MJ; Watkin JG; Wohlreich MM
    J Clin Psychiatry; 2004 Apr; 65(4):521-30. PubMed ID: 15119915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
    Coric V; Feldman HH; Oren DA; Shekhar A; Pultz J; Dockens RC; Wu X; Gentile KA; Huang SP; Emison E; Delmonte T; D'Souza BB; Zimbroff DL; Grebb JA; Goddard AW; Stock EG
    Depress Anxiety; 2010 May; 27(5):417-25. PubMed ID: 20455246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Research on association of BDNF gene Val66Met polymorphism with efficacy of antidepressants and plasma BDNF level].
    Shen X; Qian M; Yuan Y; Sun J; Zhong H; Yang J; Lin M; Li L; Guan T; Shen Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Apr; 31(2):196-200. PubMed ID: 24711031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.
    Sarris J; Stough C; Bousman CA; Wahid ZT; Murray G; Teschke R; Savage KM; Dowell A; Ng C; Schweitzer I
    J Clin Psychopharmacol; 2013 Oct; 33(5):643-8. PubMed ID: 23635869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-analysis.
    Crucitti A; Zhang Q; Nilsson M; Brecht S; Yang CR; Wernicke J
    Curr Med Res Opin; 2010 Nov; 26(11):2579-88. PubMed ID: 20874076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
    Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Schläfke S; Dienel A
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):859-69. PubMed ID: 24456909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.